Short Interest in Jasper Therapeutics, Inc. (NASDAQ:JSPR) Drops By 15.5%

Jasper Therapeutics, Inc. (NASDAQ:JSPR) was the target of a large decline in short interest in the month of January. As of January 31st, there was short interest totalling 2,720,000 shares, a decline of 15.5% from the January 15th total of 3,220,000 shares. Approximately 24.2% of the shares of the company are short sold. Based on an average daily volume of 477,000 shares, the days-to-cover ratio is presently 5.7 days.

Institutional Investors Weigh In On Jasper Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of JSPR. Jane Street Group LLC acquired a new position in Jasper Therapeutics during the third quarter valued at $251,000. Samsara BioCapital LLC boosted its stake in shares of Jasper Therapeutics by 11.4% during the 3rd quarter. Samsara BioCapital LLC now owns 584,642 shares of the company’s stock worth $10,997,000 after acquiring an additional 59,642 shares in the last quarter. Barclays PLC boosted its stake in shares of Jasper Therapeutics by 320.7% during the 3rd quarter. Barclays PLC now owns 16,146 shares of the company’s stock worth $304,000 after acquiring an additional 12,308 shares in the last quarter. Wellington Management Group LLP bought a new stake in shares of Jasper Therapeutics during the 3rd quarter worth about $447,000. Finally, Ally Bridge Group NY LLC boosted its stake in shares of Jasper Therapeutics by 82.7% during the 3rd quarter. Ally Bridge Group NY LLC now owns 399,466 shares of the company’s stock worth $7,514,000 after acquiring an additional 180,852 shares in the last quarter. 79.85% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. HC Wainwright reduced their price target on Jasper Therapeutics from $60.00 to $40.00 and set a “buy” rating for the company in a research report on Friday, January 10th. UBS Group assumed coverage on Jasper Therapeutics in a research report on Thursday. They set a “buy” rating and a $38.00 price target for the company. BMO Capital Markets assumed coverage on Jasper Therapeutics in a research report on Friday, December 6th. They set an “outperform” rating and a $63.00 price target for the company. JMP Securities reiterated a “market outperform” rating and set a $70.00 price target on shares of Jasper Therapeutics in a research report on Monday, January 6th. Finally, Royal Bank of Canada reduced their price target on Jasper Therapeutics from $68.00 to $48.00 and set an “outperform” rating for the company in a research report on Thursday, January 9th. Eleven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $64.44.

Jasper Therapeutics Trading Down 1.9 %

Shares of Jasper Therapeutics stock traded down $0.12 on Monday, reaching $6.08. 477,987 shares of the company were exchanged, compared to its average volume of 671,338. The stock has a fifty day moving average price of $12.46 and a 200-day moving average price of $17.43. The firm has a market capitalization of $91.21 million, a price-to-earnings ratio of -1.28 and a beta of 2.11. Jasper Therapeutics has a fifty-two week low of $4.55 and a fifty-two week high of $31.01.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.